Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Tess Romero. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Taylor Hanley and Adhiraj Chauhan from the team. We are pleased to welcome Agios to kick off our Wednesday here. And speaking on behalf of the company, we have CEO, Brian Goff.
Before I turn it over to Brian, I just wanted to remind folks that there will be a Q&A after the formal presentation. There is an Ask a Question button in the portal, I'm happy to ask the question on your behalf, and then we'll also have a mike runner to take live audience questions.
So with that, Brian, over to you.
All right. Well, thank you, Tess, and good morning, everyone. Agios' mission is to develop transformative treatments for patients living with rare diseases, and it's truly my pleasure to speak with you today about our strategy for significant growth
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |